press center press release



Copenhagen, August 1, 2014 – NASDAQ OMX Nordic today announced that Onxeo SA is admitted to trading and official listing on NASDAQ OMX Copenhagen. Onxeo is a Mid Cap company in the Health Care sector and will be trading under its short name ONXEO and ISIN code FR0010095596. Onxeo is the 14th company to list at NASDAQ OMX’s Nordic main markets in 2014 (NASDAQ OMX Stockholm; Helsinki; Copenhagen and Iceland).

Onxeo is a company which specialises in the development of medicinal products for the treatment of rare cancer diseases; an area in which Onxeo sees an unmet need for treatment. From August 1 Onxeo is the name of the merged companies BioAlliance Pharma SA and Topotarget A/S. The merger took effect on July 22., 2014. Onxeo has its primary listing on Euronext Paris.

Adam Kostyál, SVP Global Corporate Client Group, NASDAQ OMX Nordic said: “We are very pleased to welcome Onxeo onto the NASDAQ OMX Copenhagen main market, where new investors and existing shareholders can take part in the continued company’s future development. We are proud that Onxeo recognises the value of listing at the NASDAQ OMX Copenhagen exchange and we look forward to partnering with the new company in offering the liquidity and visibility, that a listing on an international exchange can offer.”

About NASDAQ OMX Group

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.  As the creator of the world’s first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,200 listed companies with a market value of over $8 trillion and more than 10,000 corporate clients. To learn more, visit

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties.  NASDAQ OMX cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information.  Such forward-looking statements include, but are not limited to, statements about our capital return initiatives.  Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX’s control.  These factors include, but are not limited to, NASDAQ OMX’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in NASDAQ OMX’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on NASDAQ OMX’s website at and the SEC’s website at  NASDAQ OMX undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Javier Lopez Garrido

tel. +45 3377 0430

In This Story

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more